IGF-1 LR3 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Very limited controlled human trial data.

Animal evidence: Rodent anabolic and growth-factor signaling studies inform the mechanism.

Introduction & Mechanism of Action

Long-arginine3 IGF-1 analog studied for anabolic and growth-factor signaling research.

Modified IGF-1 with reduced binding-protein affinity, extending its active half-life well beyond native IGF-1 and producing a more sustained anabolic and insulin-like signal.

Receptors/targets: IGF-1 receptor, Some cross-reactivity with the insulin receptor at high concentrations

Areas of Research Interest

• Anabolic-signaling research
• Growth-factor studies

Benefits Reported in Research

• Anabolic-signaling research
• Growth-factor studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 20–50 mcg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on IGF-1 LR3 reports administration at 20–50 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 0.1 mg vial with 2 mL bacteriostatic water, yielding a concentration of 0.05 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Hypoglycemia
• Injection-site reaction
• Water retention

Contraindications

• Active or history of malignancy (theoretical concern given growth-factor mechanism)
• Diabetes or hypoglycemia risk without close monitoring
• Pregnancy

Drug interactions

• Insulin or other glucose-lowering medications — significantly increased hypoglycemia risk

Safety

• Hypoglycemia is a specifically flagged concern in the literature due to insulin-receptor cross-reactivity
• Theoretical concern regarding unchecked cell proliferation given growth-factor mechanism

Modified for extended half-life versus native IGF-1; long-term human safety data is limited and hypoglycemia risk is a known concern in the literature.

Expected Results & Comparison

Unlike the GHRH/ghrelin-pathway secretagogues in this category (which stimulate the body's own GH/IGF-1 axis), IGF-1 LR3 is a direct IGF-1 analog — a categorically different and, per the literature, higher-hypoglycemia-risk mechanism than upstream secretagogues.

References

Continue